Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1)
- 28 November 2000
- journal article
- review article
- Published by Elsevier in Transfusion Science
- Vol. 23 (3), 211-223
- https://doi.org/10.1016/s0955-3886(00)00089-8
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Salivary Measurement of Deferiprone Concentrations and Correlation with Serum LevelsTherapeutic Drug Monitoring, 1997
- Evaluation of a new method of administration of the iron chelating agent deferoxamineThe Journal of Pediatrics, 1997
- Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugsToxicology Letters, 1995
- Selection of a new generation of orally active α‐ketohydroxypyridine iron chelators intended for use in the treatment of iron overloadAmerican Journal of Hematology, 1993
- Design, Properties, and Effective Use of the Oral Chelator L1 and OtherAnnals of the New York Academy of Sciences, 1990
- L1 (1,2‐dimethyl‐3‐hydroxypyrid‐4‐one) for oral iron chelation in patients with beta‐thalassaemia majorBritish Journal of Haematology, 1990
- The effect of synthetic iron chelators on bacterial growth in human serumFEMS Microbiology Letters, 1988
- Orally Active Alpha-Ketohydroxypyridine Iron Chelators: Effects on Iron and Other Metal MobilisationsActa Haematologica, 1987
- The study of iron mobilisation from transferrin using α-ketohydroxy heteroaromatic chelatorsBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1986
- Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron OverloadNew England Journal of Medicine, 1977